ALSO NOTED: Nautilus files IND; Inforsense raises $10M; and much more...

> Nautilus Biotech has filed an IND for injectable Belerofon, its protease-resistant, long-lasting Interferon alpha. Release

> Inforsense has gained $10 million from investors. Release

> Theravance has released additional positive data from its Phase III trial of Telavancin for infections caused by Gram-positive bacteria. Release

> Schering-Plough has sued GeoPharma in a patent infringement case involving a copycat version of Clarinex. Report

> Daiichi Pharmaceutical has signed an agreement to acquire 100 percent of shares in Daiichi Pharmaceutical Korea. Release

And Finally… A viral disease has been sweeping through southern India and is being carried around the world by travelers. Article

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.